

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 149 545
A2

12

EUROPEAN PATENT APPLICATION

21 Application number: 85300229.3

51 Int. Cl. 4: **A 61 K 31/615**
A 61 K 45/06

22 Date of filing: 14.01.85

30 Priority: 16.01.84 US 571043

43 Date of publication of application:
24.07.85 Bulletin 85/30

84 Designated Contracting States:
BE CH DE FR IT LI LU NL SE

71 Applicant: **THE PROCTER & GAMBLE COMPANY**
301 East Sixth Street
Cincinnati Ohio 45201(US)

72 Inventor: **Brand, Larry Milton**
7543 Whitehall Circle
West Chester Ohio 45069(US)

74 Representative: **Brooks, Maxim Courtney et al,**
Procter & Gamble (NTC) Limited Whitley Road
Longbenton
Newcastle-upon-Tyne NE12 9TS(GB)

84 **Pharmaceutical products providing enhanced analgesia.**

87 **An analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs is disclosed. This combination has been found to exhibit unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.**

PHARMACEUTICAL PRODUCTS PROVIDING
ENHANCED ANALGESIA

Larry M. Brand

TECHNICAL FIELD

The present invention relates to analgesic compositions comprising capsaicin or a capsaicin analog combined with a drug selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic compounds. These compositions, when administered to humans or lower animals, provide a synergistic analgesic effect while minimizing undesirable side effects and toxicity.

Capsaicin and its derivatives appear to produce an analgesic effect through a mechanism largely unrelated to that of the other two categories of analgesics, opioids (narcotics) and non-steroidal analgesics (aspirin-like drugs). Since both capsaicin and the non-steroidals produce an analgesic effect, although apparently through different mechanisms, it might be expected that their combined effect would be at best additive. However, tests have shown that the analgesic effect of the combination is not merely the sum of the effects of each component, but rather an unexpected, greatly enhanced synergistic effect. Furthermore, the undesirable side effects of the two categories of analgesics are not closely related and the addition of the second analgesic does not appear to potentiate the side effects of the first. It is therefore possible to combine the two analgesics in such a dosage as to provide greatly enhanced analgesia with no enhancement of side effects. Depending on the dosages employed, the capsaicin may either potentiate the degree of analgesia beyond that obtainable using the non-steroidal alone, or it may induce analgesia at dosages where no analgesic effect is obtained from either component alone.

BACKGROUND OF THE INVENTION

Traditionally, analgesics have fallen into two broad categories. Simple, non-narcotic analgesics, such as aspirin, which appear to work by inhibition of prostaglandin synthetase, are effective against pain of integumental origin such as headache and muscle aches, but are often ineffective in controlling deeper, more intense pain. Furthermore, they may cause undesirable side effects even at therapeutic dosages. The most common of these side effects is a propensity to induce dyspepsia and gastrointestinal bleeding. At higher dosages, the salicylates may have toxic effects on the central nervous system consisting of stimulation (including convulsions) followed by depression. Headache, dizziness, mental confusion, hearing difficulties and hyperventilation may also occur. Gastrointestinal symptoms may include epigastric distress, nausea and vomiting. The narcotic analgesics appear to work through interaction with the endorphin/enkephalin receptor system of the central nervous system and are useful in controlling pain which is too intense to be controlled by the weaker, non-narcotic analgesics. However, centrally-acting narcotic analgesics have several serious undesirable side effects, including the development of physical dependence and tolerance, sedation, respiratory depression, hypotension, increase in cerebrospinal fluid pressure, nausea, vomiting and constipation. In some patients, particularly the chronically ill, the narcotic side effects make it impossible to administer dosages sufficient to adequately control pain over the required time period.

This invention combines capsaicin or a capsaicin analog with a drug from the class of non-narcotic, non-steroidal anti-inflammatory, antipyretic and analgesic compounds (often referred to as an "aspirin-like" drug, since

the prototypical compound is aspirin), producing a synergistic increase in analgesia without a corresponding increase in side effects. The degree of analgesia produced by this combination has been found in some cases to be equivalent to that formerly obtainable only through the use of narcotics. Thus, the claimed combination makes it possible to control pain which is too severe to be adequately controlled by the non-steroidals alone, while avoiding the serious side effects and addiction potential inherent in the use of opioids.

It has been recently discovered that capsaicin, a natural product of certain species of the genus Capsicum, induces analgesia. Capsaicin (8-methyl-N-vanillyl-6Z-nonenamide) and "synthetic" capsaicin (N-vanillyl-nonanamide) are disclosed as analgesics in U.S. Patent 4,313,958, LaHann, issued February 2, 1982. Analgesic activity of capsaicin has also been discussed in the chemical and medical literature, including Yaksh, et al, Science, 206, pp 481-483 (1979); Jancso, et al, Naunyn-Schmiedeberg's Arch. Pharmacol., Vol. 311, pp 285-288 and Holzer et al, Eur. J. Pharm. Vol. 58, pp 511-514 (1979). U.S. Patent 4,238,505, Nelson, issued December 9, 1980, discloses 3-hydroxyacetanilide for use in producing analgesia in animals. European Patent Application 0089710, LaHann, et al, published September 28, 1983, describes hydroxyphenylacetamides with analgesic and anti-irritant activity. Similarly, analgesic and anti-irritant activity is disclosed for N-vanillylsulfonamides in U.S. Patent 4,401,663, Buckwalter, et al, issued August 30, 1983; N-vanillylureas in European Patent Application 0068590, Buckwalter, et al, published January 5, 1983; N-vanillylcarbamates in European Patent Application 0068592, Buckwalter, et al, published January 5, 1983; N-[(substituted phenyl)methyl]alkynlamides in U.S. Patent Application Serial No. 514,204, Janusz, et al, Filed July 14, 1983; methylene substituted N-[(substi-

- 4 -

-tuted phenyl)methyl]-alkanamides in U.S. Patent Application Serial No. 514,205, Janusz, et al, filed July 14, 1983; N[(substituted phenyl)methyl]-cis-monounsaturated alkenamides in U.S. Patent Application Serial No. 514,206, LaHann, et al, filed July 14, 1983; and N-
 5 [substituted phenyl)methyl]-diunsaturated amides in U.S. Patent Application Serial No. 514,207, LaHann, et al, filed July 14, 1983. However, none of these references suggest in any way the desirability of concurrent administration of capsaicin or a capsaicin derivative with
 10 a non-steroidal. Further, the art suggests that it is extremely difficult to predict when a synergistic effect will be obtained from the concurrent administration of two pharmaceutical compounds which take effect through different mechanisms.


15 Although there are many patents which disclose analgesic and anti-inflammatory compositions containing a combination of two or more mechanistically unrelated analgesic and/or anti-inflammatory compounds, none of these compounds has a structure at all similar to that of
 20 capsaicin. See U.S. Patent 4,404,210, Schmidt, issued September 13, 1983; U.S. Patent 4,083,981, Yamamoto, issued April 11, 1978; U.S. Patent 4,315,936, Capetola et al, issued February 16, 1982; U.S. Patent 4,379,789, Capetola et al, issued April 12, 1983; and U.S. Patent
 25 4,275,059, Flora, et al, issued June 23, 1981.

Thus, based on the art, one could not have predicted that the combination of capsaicin or a capsaicin analog with a non-steroidal would result in a synergistic increase in analgesia.

30

SUMMARY OF THE INVENTION

It has now been found that combinations of capsaicin derivatives of the general formula



wherein R_1 is OH or OCH_3 , R_2 is OH or a short-chain

ester, X is $NHC(=O)$, $NHCO(=O)$, $NHCN(=O)H$, $NHCN(=S)H$, $CN(=O)H$, or $NHS(=O)_2$,

and R is a C_5 - C_{11} alkyl, C_5 - C_{11} alkenyl, C_{11} - C_{23} cis alkenyl, C_{11} - C_{23} alkynyl, C_{11} - C_{23} alkadienyl, or C_{11} - C_{23} methylene substituted alkane, with a non-steroidal analgesic at weight ratios of capsaicinoid to non-steroidal from about 20:1 to 1:20, and preferably from about 10:1 to 1:10, provide unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.

Another aspect of the present invention comprises the method of alleviating pain in humans and lower animals by concurrent administration of a safe and effective amount of the analgesic composition described above.

15 DETAILED DESCRIPTION OF THE INVENTION

Definitions

By the term "comprising" as used herein is meant that various other inert ingredients, compatible drugs and medicaments, and steps can be employed in the compositions and methods of the present invention as long as the critical capsaicinoid/non-steroidal combination is present in the compositions and is used in the manner disclosed. The term "comprising" thus encompasses and includes the more restrictive terms "consisting essentially of" and "consisting of" which characterize the use of the compositions and methods disclosed herein.

By "compatible" herein is meant that the components of the composition are capable of being commingled without interacting in a manner which would substantially decrease the analgesic efficacy of the total composition under ordinary use situations.

By "administer concurrently" is meant either the administration of a single composition containing both the capsaicinoid and the non-steroidal, or the administration of the capsaicinoid and the non-steroidal as separate compositions within a short enough time period that the effective result is equivalent to that obtained when both compounds are administered as a single composition. Normally this would involve two separate dosages given within 10 minutes of each other. However, since many capsaicinoids retain effectiveness over unusually long time periods (possibly up to 3 days in the same cases) and most non-steroidals provide effective analgesia for relatively short time periods (4-8 hours), it may be desirable in some cases to implement a therapeutic regimen whereby each component is administered according to a schedule determined by its own period of analgesic effectiveness in order to maintain optimum effectiveness of the combination. The preferred method of administration is as a single composition.

20 All percentages and ratios herein are by weight unless otherwise specified.

Compositions


The compositions of the present invention comprise a safe and effective amount of:

- 25 (a) capsaicin or a capsaicin analog,
(b) a compound selected from the group of non-steroidal anti-inflammatory, antipyretic and analgesic drugs, and their pharmaceutically-acceptable salts; and
(c) a pharmaceutically-acceptable carrier.

30 A safe and effective amount of the composition is that amount which provides analgesia, thereby alleviating or preventing the pain being treated at a reasonable benefit/risk ratio, as is intended with any medical treatment. Obviously, the amount of the composition used will

vary with such factors as the particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), the method of administration, and the specific formulation and carrier employed.

By the term "capsaicin or a capsaicin analog" or "capsaicinoid" is meant a compound of the general formula



10 wherein R_1 is selected from the group consisting of OH and OCH_3 , R_2 is selected from the group consisting of

OH and OCR_3 , R_3 is selected from the group consisting of a C_1-C_4 alkyl, phenyl and methyl, X is selected from the

group consisting of $-NHC(=O)-$, $-NHCO(=O)-$, $-CNH(=O)-$, $NHC(=O)NH$, $NHC(=S)NH$,

15 $NHS(=O)$, and R is selected from the group consisting

of a C_5-C_{11} alkyl, C_5-C_{11} alkenyl, $C_{11}-C_{23}$ cis alkenyl, $C_{11}-C_{23}$ alkynyl, $C_{11}-C_{23}$ alkadienyl and $C_{11}-C_{23}$ methylene substituted alkane.

Preferred compounds include those wherein both

20 R_1 and R_2 are OH and X is $CNH(=O)$ or $NHC(=O)$; and those wherein

R_1 is OCH_3 , R_2 is OH or R_3CO and X is $CNH(=O)$, $NHC(=O)$ or $NHC(=S)NH$.

Preferred R groups include C_7-C_{10} alkyls and trans alkenyls, and $C_{16}-C_{21}$ cis alkenyls and alkadienyls. The preferred moieties within these

groups include C_8H_{17} , C_9H_{17} and $C_{17}H_{33}$. Preferred capsaicin analogs include N-vanillyl-alkadienamides, N-vanillyl-alkanedienyls, and N-vanillyl-cis-monounsaturated alkenamides. A particularly preferred capsaicinoid is N-vanillyl-9E-octadecenamide (N-vanillyloleamide).

Preferred capsaicin analogs and methods for their preparation are described in the following Patents and Patent Applications, all incorporated by reference herein: Capsaicin (8-methyl-N-vanillyl-6E-nonenamide) and "synthetic" capsaicin (N-vanillylnonanamide) are disclosed as analgesics in U.S. Patent 4,313,958, LaHann, issued February 2, 1982. European Patent Application 0089710, LaHann, et al, published September 28, 1983, describes hydroxyphenylacetamides with analgesic and anti-irritant activity. Similarly, analgesic and anti-irritant activity is disclosed for N-vanillylsulfonamides in European Patent Application 0068591, Buckwalter, et al, published January 5, 1983; N-vanillylureas in European Patent Application 0068590, Buckwalter, et al, published January 5, 1983; N-vanillylcarbamates in European Patent Application 0068592, Buckwalter, et al, published January 5, 1983; N-[(substituted phenyl)methyl] alkynylamides in U.S. Patent Application Serial No. 514,204, Janusz, et al, filed July 14, 1983; methylene substituted-N-[(substituted phenyl)methyl]-alkanamides in U.S. Patent Application Serial No. 514,205, Janusz, et al, filed July 14, 1983; N[(substituted phenyl)methyl]-cis-monounsaturated alkenamides in U.S. Patent Application Serial No. 514,206, LaHann, et al, filed July 14, 1983; and N-[(substituted phenyl)methyl]-diunsaturated amides in U.S. Patent Application Serial No. 514,207, LaHann, et al, filed July 14, 1983.

By "non-steroidal anti-inflammatory, antipyretic and analgesic drugs", or "non-steroidal", is meant a heterogeneous group of compounds, often chemically un-

-related (although most of them are organic acids) which share certain therapeutic actions and side effects. Their therapeutic activity appears to depend to a large extent upon the inhibition of prostaglandin biosynthesis.

- 5 Their primary use is to provide symptomatic relief from pain and inflammation associated with certain diseases, particularly musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. These compounds are often referred to as "aspirin-like drugs", since the proto-
- 10 typical compound is aspirin. The pharmacological properties and therapeutic uses of the compounds included within this classification are described in detail in Goodman and Gilman, "Analgesic-Antipyretics and Anti-Inflammatory Agents; Drugs Employed in the Treatment of
- 15 Gout", The Pharmacological Basis of Therapeutics, 6th Ed., Ch. 29 (1980); Verbeeck et al, "Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs", Clinical Pharmacokinetics 8, pp 297-331 (1983), and Scherrer and Whitehouse, Antiinflammatory Agents Chemistry &
- 20 Pharmacology, Vol. 1, Academic Press, New York (1974); all incorporated by reference herein.

Specific classes of non-steroidals useful in the present invention are disclosed in detail in the following U.S. Patents, all incorporated by reference herein:

- 25 U.S. Patent 4,275,059, Flora, et al, issued June 23, 1983, discloses salicylic acid, its pharmaceutically-acceptable salts, and its pharmaceutically-acceptable esters and derivatives; U.S. Patent 4,264,582, Flora, et al, issued April 28, 1981, discloses p-(isobutylphenyl)
- 30 acetic acid compounds, including the parent acid (ibufenac) and its salts and esters, and derivatives thereof; U.S. Patent 4,282,214, Flora, et al, issued August 4, 1981, discloses various phenylacetic acid derivatives, their pharmaceutically-acceptable salts, and their

- 10 -

pharmaceutically-acceptable esters; U.S. Patent 4,216,212, Flora, et al, issued August 5, 1980, discloses pyrazolidine compounds, their pharmaceutically-acceptable salts, and their pharmaceutically-acceptable esters; U.S. Patent 5 4,269,828, Flora, et al, issued May 26, 1981, discloses indole compounds, their pharmaceutically-acceptable salts, and their pharmaceutically-acceptable esters.

Specifically preferred non-steroidals may be roughly divided into four general classifications. The 10 salicylates include compounds such as acetylsalicylic acid (aspirin), salicylic acid, sodium salicylate, diflunisal, and methyl salicylate. The salicylate-like anti-inflammatory agents include compounds such as phenylbutazone, indomethacin, zomapi rac acid, sulindac, fluproquazone, 15 and mefenamic acid. The arylalkanoic acids include ibuprofen, naproxen, ketoprofen, fenoprofen, suprofen, flurbiprofen, benoxaprofen, piroprofen, and carprofen. The salicylate-like analgesic-antipyretics include acetaminophen and phenacetin. In some cases, the non-steroidal 20 als may be mixed with each other or with other drugs such as caffeine. Two popular analgesic combinations are aspirin, phenacetin and caffeine (APC) and aspirin, phenacetin and acetaminophen. Non-steroidals most preferred for use in the capsaicinoid-non-steroidal combination 25 include acetylsalicylic acid (aspirin), ibuprofen, acetaminophen, diflunisal, naproxen, fenoprofen, and mefenamic acid. A specifically preferred combination is APC.

Weight ratios of capsaicinoid to non-steroidal 30 useful in the present invention range from about 20:1 to about 1:20, with the preferred ratio ranging from about 10:1 to about 1:10. The optimum weight ratio is dependent primarily upon the relative strength of the particular capsaicinoid and non-steroidal used, and the 35 type of severity of the pain being treated. As a repre-

-sentative example, preferred weight ratios of capsaicinoid:acetylsalicylic acid (aspirin) may range from about 3:1 to about 1:3; preferred weight ratios of capsaicinoid:diflunisal may range from about 3:1 to about 1:3; preferred weight ratios of capsaicinoid:acetaminophen may range from about 3:1 to about 1:3; and preferred weight ratios of capsaicinoid:ibuprofen may range from about 5:1 to about 1:5. The preferred weight ratio for the preferred combination of N-vanillyl-9E-octadecenamide and aspirin is about 2:1.

By "pharmaceutically acceptable salts" is meant those salts of the above disclosed acids which are toxicologically safe for topical or oral administration. These include the sodium, calcium, potassium, magnesium, ammonium, lysine, and arginine salts.

By "pharmaceutically acceptable carrier" is meant a solid or liquid filler, diluent or encapsulating substance which may be safely used in systemic or topical administration. Depending upon the particular route of administration, a variety of pharmaceutically-acceptable carriers, well-known in the art, may be used. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances. The amount of the carrier employed in conjunction with the capsaicinoid/opioid combination is sufficient to provide a practical quantity of material per unit dose of analgesic.

Pharmaceutically-acceptable carriers for systemic administration, that may be incorporated into the compositions of this invention, include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water. Specific pharmaceutically-acceptable carriers are described in the

following U.S. Patent Applications, all incorporated by reference herein: U.S. Patent No. 4,401,663, Buckwalter, et al, issued August 30, 1983; European Patent Applications 089710, LaHann, et al, published September 28, 1983; and European Patent Application 0068592, Buckwalter, et al, published January 5, 1983. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, aqueous ethanol, sesame oil, corn oil, and combinations thereof.

10 Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, 15 diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent 20 preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring, and flavoring agents. Preferred carriers for oral administration include ethyl 25 oleate, methyl cellulose, gelatin, propylene glycol, cottonseed oil, sesame oil, peanut oil, corn oil, soybean oil, oil and water emulsions, and self-emulsifying oils either as free-flowing liquids or encapsulated in soft gelatin capsules. Specific examples of pharmaceutically-acceptable carriers and excipients that may be 30 used to formulate oral dosage forms, which may be used in formulating oral dosage forms containing monoalkenamides, are described in U.S. Patent 3,903,297. Robert, issued September 2, 1975, incorporated by reference herein.

35 Techniques and compositions for making solid oral dosage

forms are described in Marshall, "Solid Oral Dosage Forms", Modern Pharmaceuticals, Vol. 7, (Banker and Rhodes, editors), 359-427 (1979), incorporated by reference herein.

Specific systemic and topical formulations useful
5 in this invention are described in the following U.S.
Patent Applications, relating to specific capsaicin
analogs and methods of treatment, which are incorporated
by reference herein: U.S. Patent No. 4,401,663, Buck-
walter, et al, issued August 30, 1983; and European Patent
10 Application 0089710; LaHann, et al, published September
28, 1983; European Patent Application 0068590, Buckwalter,
et al, published January 5, 1983; and European Patent
Application 0068592, Buckwalter, et al, published January
5, 1983. Topical vehicles, useful herein, are disclosed
15 in the following U.S. Patent Applications, incorporated by
reference herein: "Improved Penetrating Topical Pharma-
ceutical Compositions Combining 1-dodecylazacycloheptan-2-
one", Serial No. 506,275, Cooper, filed June 21, 1983;
"Penetrating Topical Pharmaceutical Compositions Containing
20 N-(1-hydroxyethyl)-pyrrolidone", Serial No. 506,273,
Cooper, filed June 21, 1983; and "Compounds Useful for
Producing Analgesia", Serial No. 514,206, LaHann and
Buckwalter, filed July 14, 1983.

Methods for Producing Analgesia

25 The present invention also encompasses methods for
providing analgesia in humans or lower animals by ad-
ministering concurrently to the human or lower animal in
need of such treatment a safe and effective amount of a
capsaicinoid/non-steroidal combination or a composition
30 containing the same. Dosages required, as well as methods
of administration, are dependent on the type of non-
steroidal employed, the physical condition of the patient,
the severity of the pain which must be prevented or
alleviated, the relative severity and importance of ad-
35 verse side effects, and other factors within the judgment

of the physician. The preferred method of administration in most cases will be orally.

The maximum dosage of the preferred capsaicin analogue vanillyl oleamide (VO) which would normally be administered orally to an average adult without unacceptable side effects is about 2000 mg (35.4 mg/kg). The minimum effective dosage is about 50 mg (0.85 mg/kg). The maximum dosage of a non-steroidal which can be administered to the average adult is also about 2000 mg (35.4 mg/kg). Thus, the maximum allowable dosage of the combination will be about 2000 mg (35.4 mg/kg). It should be noted that a sub-effective dosage of one compound may effectively potentiate the other compound; therefore, less-than-minimum dosages of each component may be utilized in some cases. Thus, when dealing with safe and effective dosage levels of the present invention, it is more appropriate to speak of safe and effective dosages of the combination rather than of the individual components.

The compositions and combinations of this invention can be used to treat and prevent pain and inflammation associated with certain diseases, particularly muscular-skeletal disorders, and to provide analgesia in various disorders at the deeper structures, muscles, tendons, bursa and joints associated with disease and trauma, and in various other conditions in which capsaicinoids and/or non-steroidals have heretofore been used to alleviate pain and discomfort.

The compositions of the instant invention are normally administered either topically or orally.

The following non-limiting Examples illustrate the compositions, methods of treatment, and uses of the present invention.

EXAMPLE I

An analgesic composition for oral administration was made using the following ingredients:

	N-Vanillyl-9E-octadecenamide	120 mg
5	Aspirin	60 mg
	Methylcellulose	30 mg
	Saline	6.0 ml

The composition was prepared by dissolving the methylcellulose in the saline to yield a 0.5% solution, after which the solid aspirin and N-vanillyl-9-octadecenamide were added and uniformly suspended in the solution by exposure to sonication. Male mice weighing approximately 25 g were orally dosed with a volume of this suspension sufficient to deliver 200 mg/kg of the octadecenamide and 100 mg/kg of the aspirin. Identical groups of mice were dosed orally with similarly prepared formulations which lacked either the aspirin, the octadecenamide, or both. Analgesic activity was demonstrated using the phenylquinone writhing test.

20

EXAMPLE II

An analgesic composition for oral administration was made using the following ingredients:

	N-vanillyl-9E-octadecenamide	120 mg
	Ibuprofen	30 mg
25	Methylcellulose	30 mg
	Saline	6.0 ml

The methylcellulose suspending agent was dissolved in the saline to yield a 0.5% solution, to which the two drugs were added. A homogeneous suspension was achieved by the aid of sonication. Male mice weighing approximately 25 g were dosed by gavage with 250 mg/kg of the mixture. Analgesic activity was demonstrated using the phenylquinone writhing test.

mixture. Analgesic activity was demonstrated using the phenylquinone writhing test.

EXAMPLE III

An analgesic composition for oral administration
5 was made using the following ingredients:

N-vanillyl-9E-octadecenamide	120 mg
Ibuprofen	30 mg
Ethyl oleate	6.0 ml

The two analgesic agents were suspended in the
10 ethyl oleate with the aid of sonication, and analgesic activity was demonstrated using the phenylquinone writhing test.

EXAMPLE IV

An analgesic composition for oral administration is
15 made using the following ingredients:

N-vanillyl-9E-octadecenamide	100 g
Acetylsalicylic acid	100 g
Ethyl oleate	300 g

The composition is made by simple dissolution of
20 the octadecenamide in the ethyl oleate, followed by suspension of the finely divided acetylsalicylic acid in the resulting solution by vigorous mechanical blending under an inert atmosphere of argon or dry nitrogen. The creamy suspension is then loaded into soft gelatin cap-
25 sules to deliver 325 mg acetylsalicylic acid and 325 mg N-vanillyl-9-octadecenamide per capsule. One such capsule is administered orally to a 60 kg human, producing analgesia.

Substantially similar results are produced when the
30 octadecenamide is replaced, in whole or in part, by capsaicin; N-vanillyl-9Z-octadecenamide; N-vanillyl-9E-octadecenamide; N-[(4-acetoxy-3-methoxyphenyl)methyl]-9Z-octadecenamide; N-vanillyl-(Z,Z)-9,12-octadecadienamide; N-vanillyl-(E,E)-9,12-octadecadienamide; N-[(4-acetoxy-3-
35 methoxyphenyl)methyl]-(E,E)-9,12-octadecadienamide;

N-vanillyl-(E,E)-10,13-nonadecadienamide; N-vanillyl-9-octadecanamide; 9-methylene-N-octadecanamide; 9-methylene-N-[(4-acetoxy-3-methoxyphenyl)-methyl]octadecanamide; 4-acetoxy-3-methoxy-benzyl nonamide, or octyl 3,4-dehydroxyphenylacetamide.

Substantially similar results are also obtained when the acetylsalicylic acid is replaced, in whole or in part, by the sodium, calcium, or lysine salts of aspirin, ibuprofen, diflunisal, naproxen, mefenamic acid, fenoprofen, 10 indomethacin, ketoprofen, suprofen, perprofen, carprofen, or an aspirin-phenacetin-caffeine combination (APC).

EXAMPLE V

A composition for oral administration is made with the following components:

15

	<u>Bulk</u>	<u>Individual Tablet</u>
N-vanillyl-9,12-octadecadienamide	140 g	350 mg
Ibuprofen	35 g	90 mg
Starch	12 g	30 mg
20 Magnesium stearate	2 g	5 mg
Microcrystalline cellulose	40 g	100 mg
Colloidal silicon dioxide	1 g	2.5 mg
Povidone	5 g	12.5 mg

The above ingredients are admixed in bulk and 25 formed into compressed tablets, using tabletting methods known in the art, each containing 590 mg of the mixture. One such tablet is administered orally to a 60 kg human, producing analgesia.

EXAMPLE VI

30 A composition for oral administration is made with the following ingredients:

N-vanillyl-9E-octadecenamide	225 g
Aspirin	125 g
Phenacetin	83 g

- 18 -

	Caffeine	17 g
	Mannitol	487 g
	Acacia	29.3 g
	Starch	48.1 g
5	Talc	15 g
	Calcium stearate	2 g

The above ingredients are admixed in bulk and formed into tablets weighing 100 mg each using tabletting methods known in the art. Two such tablets are administered orally to a 70 kg human, producing analgesia.

EXAMPLE VII

A composition for transdermal topical delivery is made by admixing the following components:

	N-vanillyl-9,12,15[E,E,E]-octadecatrienamide	4.0%
15	Ibuprofen	1.0%
	Myristyl alcohol	1.0%
	Propylene glycol	94.0%

Approximately 4.0 ml of the lotion is applied to an 80 sq. cm. portion of the skin of a 60 kg human, producing analgesia.

Effectiveness in Providing Analgesia

Phenylquinone Writhing Tests

The extent of analgesia obtained was determined using the phenylquinone writhing test model. Groups of 25 eight male mice weighing between approximately 25 and 30g were dosed orally by gavage with the analgesic composition to be tested. Identical groups of mice were dosed with control compositions. Three hours after this initial administration, the mice were injected intraperitoneally with a 0.2% solution of phenylbenzoquinone in aqueous ethanol. The ability of the analgesic compositions tested to relieve the discomfort induced was measured by counting the number of abdominal contractions, or "writhes", occurring in each mouse during a 10 minute period be-

-ginning 10 minutes after injection of the phenylbenzo-quinone solution. The results are expressed as a percent of the "writhing" response observed in the vehicle control group.

5

EXAMPLE VIII

An analgesic composition for oral administration was made using the following ingredients:

	N-vanillyl-9-octadecenamide	120 mg
	Aspirin	60 mg
10	Methylcellulose	30 mg
	Saline	6.0 ml

The composition was prepared by dissolving the methylcellulose in the saline to yield a 0.5% solution, after which the solid aspirin and N-vanillyl-9-octadecen-
15 amide were added and uniformly suspended in the solution by exposure to sonication.

Male mice weighing approximately 25 g were orally dosed with a volume of this suspension sufficient to deliver 200 mg/kg of the octadecenamide and 100 mg/kg of
20 the aspirin. Identical groups of mice were dosed orally with similarly prepared formulations which lacked either the aspirin, the octadecenamide, or both. The mouse "writhing" method for assessing pain response described above was used. The data, summarized in the following
25 table, were normalized based on the vehicle control taken as 100.

	<u>Treatment</u>	<u>% Writhing Response</u>
	Methylcellulose alone	100
	Octadecenamide (200 mg/kg)	54
30	Aspirin (100 mg/kg)	78
	Aspirin (100 mg/kg) + octadecenamide (200 mg/kg)	10

The response of the group given aspirin alone was not statistically distinguishable from that of the control
35 group. The 90% inhibition of the writhing response

resulting from the combination treatment (aspirin plus octadecenamide) is greater than that expected from the sum of the aspirin treatment (22% inhibition) and octadecenamide treatment (45% inhibition) when given separately.

EXAMPLE IX

5

An analgesic combination for oral administration was prepared in a manner similar to that described for Example I, the only difference being the ratio of aspirin to N-vanillyl-9-octadecenamide:

10	N-vanillyl-9-octadecenamide	120 mg
	Aspirin	120 mg
	Methylcellulose	30 mg
	Saline	6.0 ml

A solution was prepared as described in Example I. The analgesic activity of the combination was assessed in mice using the "writhing" method described above. The activity of the combination was contrasted with those of similar formulations lacking the aspirin component, the octadecenamide component or both:

20	<u>Treatment</u>	<u>% Writhing Response</u>
	Methylcellulose alone	100
	Aspirin (200 mg/kg)	15
	Octadecenamide (200 mg/kg)	33
	Aspirin (200 mg/kg + octadecenamide (200 mg/kg)	1.5

25

The analgesic efficacy obtained from the combination is significantly greater than that from either component alone.

EXAMPLE X

An analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9-octadecenamide	120 mg
Ibuprofen	30 mg
Methylcellulose	30 mg
Saline	6.0 ml

The methylcellulose suspending agent was dissolved in the saline to yield a 0.5% solution, to which the two drugs were added. A homogeneous suspension was achieved by the aid of sonication. The analgesic efficacy of this formulation was evaluated by dosing the mice by gavage with a sufficient dosage to provide 250 mg/kg of the mixture. The analgesic strength of the treatment was assessed using the "writhing" method described above. The efficacy of the combination was compared with that of similar formulations lacking the octadecenamide, the ibuprofen, or both.

<u>Treatment</u>	<u>% Writhing Response</u>
Methylcellulose alone	100
Ibuprofen (50 mg/kg)	114
15 Octadecenamide (200 mg/kg)	48
Octadecenamide (200 mg/kg) + ibuprofen (50 mg/kg)	2

In this case, the addition of an ineffective dose of ibuprofen to a moderately effective dose of octadecenamide resulted in a greatly potentiated analgesic effect.

EXAMPLE XI

An analgesic composition for oral administration was made using the following ingredients:

	N-vanillyl-9-octadecenamide	120 mg
	Ibuprofen	30 mg
25	Ethyl oleate	6.0 ml

The two analgesics were suspended in ethyl oleate with the aid of sonication, and evaluated for analgesic efficacy exactly as described in Example X.

<u>Treatment</u>	<u>% Writhing Response</u>
30 Ethyl oleate alone	100
Octadecenamide (200 mg/kg)	36
Ibuprofen (50 mg/kg)	154
Octadecenamide (200 mg/kg) + ibuprofen (50 mg/kg)	5

- 22 -

Although the response of the group receiving 50 mg/kg of ibuprofen alone did not vary significantly from that of the control group, the addition of this sub-effective amount of ibuprofen to the octadecenamide greatly potentiated its analgesic effect. Further, the combination of ibuprofen with the octadecenamide can provide anti-inflammatory/anti-arthritis efficacy lacking in N-vanillyl-9-octadecenamide and related capsaicin analogs.

10

EXAMPLE XII

An analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9E-octadecenamide	120 mg
3-(2',4'-difluorophenyl)-salicylic acid (diflunisal)	60 mg
Ethyl oleate	6.0 ml

15

The two analgesics were suspended in ethyl oleate with the aid of sonication and were evaluated for analgesic efficacy as described in Example X.

20 TREATMENT% WRITHING RESPONSE

Ethyl oleate alone	100
Diflunisal (100 mg/kg)	121
Octadecenamide (200 mg/kg)	50
Diflunisal (100 mg/kg) + Octadecenamide (200 mg/kg)	15

25

In this case, the addition of an ineffective dose of diflunisal to a moderately effective dose of octadecenamide resulted in a greatly potentiated analgesic effect. Additionally, diflunisal provides anti-inflammatory activity not possessed by the octadecenamide alone.

30

EXAMPLE XIII

An analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9E-octadecenamide	75 mg
Acetaminophen	75 mg
Ethyl oleate/benzyl alcohol (98:2 vol/vol)	5 ml

The two analgesics were suspended in the ethyl
5 oleate solution with the aid of sonication and were
evaluated as in Example X.

<u>TREATMENT</u>	<u>% WRITHING RESPONSE</u>
Ethyl oleate solution alone	100
Acetaminophen (150 mg/kg)	127
10 Octadecenamide (150 mg/kg)	57
Acetaminophen (150 mg/kg + octadecenamide (150 mg/kg)	17

In this case, the addition of an ineffective dose
of acetaminophen to a marginally effective dose of octa-
15 decenamide resulted in a greatly potentiated analgesic
effect.

EXAMPLE XIV

In order to determine the preferred capsaicinoid:
non-steroidal ratios, an analgesic combination for oral
20 administration was made using the following ingredients:

1:1 Octadecenamide:aspirin Combination

N-vanillyl-9E-octadecenamide	75 mg
Aspirin	75 mg
Ethyl oleate	10 ml

25 1:2 Octadecenamide:aspirin Combination

N-vanillyl-9E-octadecenamide	50 mg
Aspirin	100 mg
Ethyl oleate	10 ml

1:5 Octadecenamide:aspirin Combination

30 N-vanillyl-9E-octadecenamide	25 mg
Aspirin	125 mg
Ethyl oleate	10 ml

The two analgesics were suspended in ethyl oleate
with the aid of sonication and were evaluated for anal-
35 gesic efficacy as described in Example X.

<u>TREATMENT</u>	<u>% WRITHING RESPONSE</u>
Ethyl oleate alone	100
150 mg/kg aspirin	92
150 mg/kg Octadecenamide	43
5 150 mg/kg Octadecenamide:Aspirin (1:1)	48
150 mg/kg Octadecenamide:Aspirin (1:2)	28
150 mg/kg Octadecenamide:Aspirin (1:5)	77

The responses of the ethyl oleate control group, the 1:5 combination group (25 mg/kg octadecenamide + 125 10 mg/kg aspirin) and the group receiving 150 mg/kg aspirin were not significantly different. The groups receiving the octadecenamide alone and the 1:1 combination (75 mg/kg aspirin + 75 mg/kg octadecenamide) displayed a moderate analgesic effect. The group receiving the 1:2 combination 15 (50 mg/kg octadecenamide + 100 mg/kg aspirin) displayed an analgesic effect unexpectedly superior to that of any of the other groups.

Since the aspirin component of this combination provides an anti-inflammatory benefit not possessed by the 20 octadecenamide or the other capsaicin analogs, and the octadecenamide provides greater analgesia than is obtainable using aspirin alone without many of the limitative side effects of aspirin, including gastrointestinal effects, the combination clearly provides benefits not 25 attainable using either compound alone.

EXAMPLE XV

In order to determine the preferred dosages of the capsaicinoid/non-steroidal combination in the rat, a 2:1 octadecenamide:ibuprofen analgesic composition for oral 30 administration was made using the following ingredients:

N-vanillyl-9E-octadecanamide	100 mg
Ibuprofen	50 mg
Ethyl oleate/benzyl alcohol (98:2 vol/vol)	5 ml

The two analgesics were suspended in the ethyl 35 oleate solution with the aid of sonication, and varying

dosages of the combination, as well as the individual components, were evaluated for analgesic efficacy as described in Example X.

<u>TREATMENT</u>	<u>% WRITHING RESPONSE</u>
5 Ethyl oleate solution alone	100
50 mg/kg ibuprofen	150
100 mg/kg octadecenamide	83
400 mg/kg octadecenamide	21
75 mg/kg 2:1 octadecenamide: ibuprofen combination	40
10 150 mg/kg 2:1 octadecenamide:	6
300 mg/kg 2:1 octadecenamide: ibuprofen combination	0.5


All three dosage levels of the combination produced a significant analgesic effect, although the 75 mg/kg dosage produced less analgesia than the other two dosages. Preferred dosage levels will depend on the severity of the pain to be treated, the relative severity of adverse side effects, and other factors within the judgment of the physician.

Although neither 50 mg/kg ibuprofen nor 100 mg/kg octadecenamide provided significant analgesia by themselves, the 150 mg/kg combination (100 mg/kg octadecenamide + 50 mg/kg ibuprofen) demonstrated an extremely strong analgesic effect. Furthermore, only 150 mg/kg of the 2:1 combination produced a greater analgesic effect than 400 mg/kg of octadecenamide alone, and only 75 mg/kg of the 2:1 combination (sub-effective amounts of both components) produced a greater analgesic effect than 100 mg/kg of octadecenamide alone. These results indicate a synergistic increase in analgesia when the two analgesics are combined.


WHAT IS CLAIMED IS:

1. An analgesic composition characterized in that it comprises a safe and effective amount of:

(a) an analgesic compound of the general formula



wherein R₁ is selected from OH and OCH₃, R₂ is selected from OH and OCH₃, R₃ is selected from C₁-C₄ alkyl, phenyl and methyl, X is selected from





selected from C₅-C₁₁ alkyl, C₅-C₁₁ alkenyl, C₁₁-C₂₃ cis alkenyl, C₁₁-C₂₃ alkynyl, C₁₁-C₂₃ alkadienyl and C₁₁-C₂₃ methylene substituted alkane;


(b) an analgesic selected from non-steroidal anti-inflammatory, antipyretic and analgesic compounds and their pharmaceutically-acceptable salts; and

(c) a pharmaceutically-acceptable carrier;

wherein the weight ratio of (a):(b) is from 20:1 to about 1:20.

2. A composition according to Claim 1, characterized in that R₁ and



R₂ are both OH and X is  or .

3. A composition according to Claim 1, characterized in that R₁ is OCH₃, R₂ is OH, and X is .

4. A composition according to Claim 3, characterized in that R is a C₇-C₁₀ alkyl or C₇-C₁₀ trans alkenyl.

5. A composition according to Claim 3, characterized in that R is a C₁₆-C₂₁ cis alkenyl or C₁₆-C₂₁ alkadienyl.

6. A composition according to Claim 1, characterized in that R₁ is

OCH₃, R₂ is , X is  and R is a C₇-C₁₀ alkyl or C₇-C₁₀ trans alkenyl

7. A composition according to Claim 1, characterized in that R₁ is

8. A composition according to any of Claims 1-7, characterized in that the non-steroidal is selected from salicylates and their pharmaceutically-acceptable salts.

9. A composition according to any of Claims 1-7, characterized in that the non-steroidal is selected from arylakanoic acids and their pharmaceutically-acceptable salts.

10. A composition according to any of Claims 1-7, characterized in that the non-steroidal is selected from acetylsalicylic acid, diflunisal, ibuprofen, naproxen, and acetaminophen.

11. A composition according to any of Claims 1 and 8-10, characterized in that the capsaicinoid is N-vanillyl-9-octadecenamide.



European Patent
Office

EUROPEAN SEARCH REPORT

0149545

Application number

EP 85 30 0229

DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)												
D, A	US-A-4 313 958 (THOMAS R. LAHANN) * Column 6, lines 55-68; claims 1-6 *	1-11	A 61 K 31/615 A 61 K 45/06												
A	--- ROTE LISTE, 1979, Editio Cantor, Aulendorf/Württ., DE; * No. 05 528B "Rheumaliment" * -----	1-11													
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)												
			A 61 K												
The present search report has been drawn up for all claims															
Place of search THE HAGUE		Date of completion of the search 09-04-1985	Examiner BRINKMANN C.												
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS</td><td>T : theory or principle underlying the invention</td></tr><tr><td>X : particularly relevant if taken alone</td><td>E : earlier patent document, but published on, or after the filing date</td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td>D : document cited in the application</td></tr><tr><td>A : technological background</td><td>L : document cited for other reasons</td></tr><tr><td>O : non-written disclosure</td><td>& : member of the same patent family, corresponding document</td></tr><tr><td>P : intermediate document</td><td></td></tr></table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date	Y : particularly relevant if combined with another document of the same category	D : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	& : member of the same patent family, corresponding document	P : intermediate document	
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention														
X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date														
Y : particularly relevant if combined with another document of the same category	D : document cited in the application														
A : technological background	L : document cited for other reasons														
O : non-written disclosure	& : member of the same patent family, corresponding document														
P : intermediate document															

10



Europäisches Patentamt
European Patent Office
Office européen des brevets

11

Publication number:

**0 149 545
B1**

12

EUROPEAN PATENT SPECIFICATION

45 Date of publication of patent specification: 27.12.89

51 Int. Cl.⁴: **A 61 K 31/615, A 61 K 45/06**

21 Application number: **85300229.3**

22 Date of filing: **14.01.85**

00 Divisional application 88114854 filed on 12.09.88.

54 **Pharmaceutical products providing enhanced analgesia.**

30 Priority: **16.01.84 US 571043**

43 Date of publication of application:
24.07.85 Bulletin 85/30

45 Publication of the grant of the patent:
27.12.89 Bulletin 89/52

84 Designated Contracting States:
BE CH DE FR IT LI LU NL SE

56 References cited:
US-A-4 313 958

**ROTE LISTE, 1979, Editio Cantor,
Aulendorf/Württ., DE;**

73 Proprietor: **THE PROCTER & GAMBLE
COMPANY
301 East Sixth Street
Cincinnati Ohio 45201 (US)**

72 Inventor: **Brand, Larry Milton
7543 Whitehall Circle
West Chester Ohio 45069 (US)**

74 Representative: **Brooks, Maxim Courtney et al
Procter & Gamble (NTC) Limited Whitley Road
Longbenton
Newcastle-upon-Tyne NE12 9TS (GB)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.

EP 0 149 545 B1

Description

The present invention relates to analgesic compositions comprising capsaicin or a capsaicin analog combined with a drug selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic compounds. These compositions, when administered to humans or lower animals, provide a synergistic analgesic effect while minimizing undesirable side effects and toxicity.

Capsaicin and its derivatives appear to produce an analgesic effect through a mechanism largely unrelated to that of the other two categories of analgesics opioids (narcotics) and non-steroidal analgesics (aspirin-like drugs). Since both capsaicin and the non-steroidals produce an analgesic effect, although apparently through different mechanisms, it might be expected that their combined effect would be at best additive. However, tests have shown that the analgesic effect of the combination is not merely the sum of the effects of each component, but rather an unexpected, greatly enhanced synergistic effect. Furthermore, the undesirable side effects of the two categories of analgesics are not closely related and the addition of the second analgesic does not appear to potentiate the side effects of the first. It is therefore possible to combine the two analgesics in such a dosage as to provide greatly enhanced analgesia with no enhancement of side effects. Depending on the dosages employed, the capsaicin may either potentiate the degree of analgesia beyond that obtainable using the non-steroidal alone, or it may induce analgesia at dosages where no analgesic effect is obtained from either component alone.

Traditionally, analgesics have fallen into two broad categories. Simple, non-narcotic analgesics, such as aspirin, which appear to work by inhibition of prostaglandin synthetase, are effective against pain of integumental origin such as headache and muscle aches, but are often ineffective in controlling deeper, more intense pain. Furthermore, they may cause undesirable side effects even at therapeutic dosages. The most common of these side effects is a propensity to induce dyspepsia and gastrointestinal bleeding. At higher dosages, the salicylates may have toxic effects on the central nervous system consisting of stimulation (including convulsions) followed by depression. Headache, dizziness, mental confusion, hearing difficulties and hyperventilation may also occur. Gastrointestinal symptoms may include epigastric distress, nausea and vomiting. The narcotic analgesics appear to work through interaction with the endorphin/enkephalin receptor system of the central nervous system and are useful in controlling pain which is too intense to be controlled by the weaker, non-narcotic analgesics. However, centrally-acting narcotic analgesics have several serious undesirable side effects, including the development of physical dependence and tolerance, sedation, respiratory depression, hypotension, increase in cerebrospinal fluid pressure, nausea, vomiting and constipation. In some patients, particularly the chronically ill, the narcotic side effects make it impossible to administer dosages sufficient to adequately control pain over the required time period.

This invention combines capsaicin or a capsaicin analog with a drug from the class of non-narcotic, non-steroidal anti-inflammatory, antipyretic and analgesic compounds producing a synergistic increase in analgesia without a corresponding increase in side effects. The degree of analgesia produced by this combination has been found in some cases to be equivalent to that formerly obtainable only through the use of narcotics. Thus, the claimed combination makes it possible to control pain which is too severe to be adequately controlled by the non-steroidals alone, while avoiding the serious side effects and addiction potential inherent in the use of opioids.

It has been recently discovered that capsaicin, a natural product of certain species of the genus *Capsicum*, induces analgesia. Capsaicin (8-methyl-N-vanillyl-6Z-nonenamide) and "synthetic" capsaicin (N-vanillyl-nonanamide) are disclosed as analgesics in US-A-4,313,958, LaHann, issued February 2, 1982. Analgesic activity of capsaicin has also been discussed in the chemical and medical literature, including Yaksh, et al, *Science*, 206, pp 481-483 (1979); Jancso, et al, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, Vol. 311, pp 285-288 and Holzer et al, *Eur. J. Pharm.* Vol. 58, pp 511-514 (1979). US-A-4,238,505, Nelson, issued December 9, 1980, discloses 3-hydroxyacetanilide for use in producing analgesia in animals. EP-A-0089710, La Hann, et al, published September 28, 1983, describes hydroxy-phenylacetamides with analgesic and anti-irritant activity. Similarly, analgesic and anti-irritant activity is disclosed for N-vanillylsulfonamides in US-A-4,401,663, Buckwalter, et al, issued August 30, 1983; N-vanillylureas in EP-A-0068590, Buckwalter, et al, published January 5, 1983; N-vanillylcarbamates in EP-A-0068592, Buckwalter, et al, published January 5, 1983; N-[(substituted phenyl)methyl]alkynlamides in US-A-4532139; methylene substituted N-[(substituted phenyl)methyl]alkanamides in US-A-4544668, N[(substituted phenyl)methyl]-cis-monounsaturated alkenamides in US-A-4493848; and N-[substituted phenyl)methyl]-diunsaturated amides in US-A-4544669. However, none of these references suggest in any way the desirability of concurrent administration of capsaicin or a capsaicin derivative with a non-steroidal. Further, the art suggests that it is extremely difficult to predict when a synergistic effect will be obtained from the concurrent administration of two pharmaceutical compounds which take effect through different mechanisms.

Although there are many patents which disclose analgesic and anti-inflammatory compositions containing a combination of two or more mechanistically unrelated analgesic and/or anti-inflammatory compounds, none of these compounds has a structure at all similar to that of capsaicin. See US-A-4,404,210, Schmidt, issued September 13, 1983; US-A-4,083,981, Yamamoto, issued April 11, 1978; US-A-4,315,936, Capetola et al, issued February 16, 1982; US-A-4,379,789, Capetola et al, issued


EP 0 149 545 B1

April 12, 1983; and US—A—4,275,059, Flora, et al, issued June 23, 1981.

Thus, based on the art, one could not have predicted that the combination of capsaicin or a capsaicin analog with a non-steroidal would result in a synergistic increase in analgesia.

SUMMARY OF THE INVENTION


It has now been found that combinations of capsaicin derivatives of the general formula



wherein R_1 is OH or OCH_3 , R_2 is OH or



R_3 is C_1-C_4 alkyl or phenyl,



and R is a $C_{11}-C_{23}$ *cis* alkenyl, $C_{11}-C_{23}$ alkynyl, $C_{11}-C_{23}$ alkadienyl, or $C_{11}-C_{23}$ methylene substituted alkane, with an arylalkanoic non-steroidal analgesic selected from ibuprofen, naproxen, ketoprofen, fenoprofen, suprofen, flurbiprofen, benoxoprofen, pirofen and carprofen, at weight ratios of capsaicinoid to non-steroidal from 20:1 to 1:20, and preferably from 10:1 to 1:10, provide unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.

Definitions

By the term "comprising" as used herein is meant that various other inert ingredients, compatible drugs and medicaments, and steps can be employed in the compositions and methods of the present invention as long as the critical capsaicinoid/non-steroidal combination is present in the compositions and is used in the manner disclosed. The term "comprising" thus encompasses and includes the more restrictive terms "consisting essentially of" and "consisting of" which characterize the use of the composition and methods disclosed herein.

By "compatible" herein is meant that the components of the composition are capable of being commingled without interacting in a manner which would substantially decrease the analgesic efficacy of the total composition under ordinary use situations.

By "administer concurrently" is meant either the administration of a single composition containing both the capsaicinoid and the non-steroidal, or the administration of the capsaicinoid and the non-steroidal as separate compositions within a short enough time period that the effective result is equivalent to that obtained when both compounds are administered as a single composition. Normally this would involve two separate dosages given within 10 minutes of each other. However, since many capsaicinoids retain effectiveness over unusually long time periods (possibly up to 3 days in the same cases) and most non-steroidals provide effective analgesia for relatively short time periods (4—8 hours), it may be desirable in some cases to implement a therapeutic regimen whereby each component is administered according to a schedule determined by its own period of analgesic effectiveness in order to maintain optimum effectiveness of the combination. The preferred method of administration is as a single composition.

All percentages and ratios herein are by weight unless otherwise specified.

Compositions

The compositions of the present invention comprise a safe and effective amount of:


- a specified capsaicin analog,
- a compound selected from specified non-steroidal analgesic drugs, and their pharmaceutically-acceptable salts; and
- a pharmaceutically-acceptable carrier.

A safe and effective amount of the composition is that amount which provides analgesia, thereby alleviating or preventing the pain being treated at a reasonable benefit/risk ratio, as is intended with any medical treatment. Obviously, the amount of the composition used will vary with such factors as the

EP 0 149 545 B1

particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), the method of administration, and the specific formulation and carrier employed.


By the term "capsaicin analog" or "capsaicinoid" is meant a compound of the general formula



wherein R₁ is selected from OH and OCH₃, R₂ is selected from OH and




R₃ is selected from a C₁—C₄ alkyl and phenyl, X is selected from




and R is selected from C₁₁—C₂₃ *cis* alkenyl, C₁₁—C₂₃ alkynyl, C₁₁—C₂₃ alkadienyl and C₁₁—C₂₃ methylene substituted alkane.

Preferred compounds include those wherein both R₁ and R₂ are OH and X is



and those wherein R₁ is OCH₃, R₂ is OH or R₃CO and X is



Preferred R groups include C₁₆—C₂₁ *cis* alkenyls and alkadienyls. The preferred moieties within these groups include C₁₇H₃₃. Preferred capsaicin analogs include N-vanillyl-alkadienamides, N-vanillyl-alkadienyls, and N-vanillyl-*cis*-monounsaturated alkenamides. A particularly preferred capsaicinoid is N-vanillyl-9E-octadecenamide (N-vanillyloleamide).

Preferred capsaicin analogs and methods for their preparation are described in the following Patents and Patent Applications; Capsaicin (8-methyl-N-vanillyl-6E-nonenamide) and "synthetic" capsaicin (N-vanillylnonanamide) are disclosed as analgesics in US—A—4,313,958, LaHann issued February 2, 1982. EP—A—0089710, La Hann, et al, published September 28, 1983, describes hydroxyphenylacetamides with analgesics and anti-irritant activity. Similarly, analgesic and anti-irritant activity is disclosed for N-vanillyl-sulfonamides in EP—A—0068591, Buckwalter, et al, published January 5, 1983; N-vanillylureas in EP—A—0068590, Buckwalter, et al, published January 5, 1983; N-vanillylcarbamates in EP—A—0068592, Buckwalter, et al, published January 5, 1983; N-[(substituted phenyl)methyl]alkynylamides in US—A—4,532,139; methylene substituted-N-[(substituted phenyl)methyl]-alkanamides in US—A—4,544,668; N[(substituted phenyl)methyl]-*cis*-monounsaturated alkenamides in US—A—4,493,848; and N-[(substituted phenyl)methyl]-diunsaturated amides in US—A—4,544,669.

Weight ratios of capsaicinoid to non-steroidal useful in the present invention range from 20:1 to 1:20, with the preferred ratio ranging from 10:1 to 1:10. The optimum weight ratio is dependent primarily upon the relative strength of the particular capsaicinoid and non-steroidal, used, and the type of severity of the pain being treated. As a representative example, preferred weight ratios of capsaicinoid:ibuprofen may range from 5:1 to 1:5.

By "pharmaceutically acceptable salts" is meant those salts of the above disclosed acids which are toxicologically safe for topical or oral administration. These include the sodium, calcium, potassium,

magnesium, ammonium, lysine, and arginine salts.

By "pharmaceutically acceptable carrier" is meant a solid or liquid filler, diluent or encapsulating substance which may be safely used in systemic or topical administration. Depending upon the particular route of administration, a variety of pharmaceutically-acceptable carriers, well-known in the art, may be used. These include solid or liquid fillers, diluents, hydroptropes, surface-active agents, and encapsulating substances. The amount of the carrier employed in conjunction with the capsaiconoid/opioid combination is sufficient to provide a practical quantity of material per unit dose of analgesic.

Pharmaceutically-acceptable carriers for systemic administration, that may be incorporated into the compositions of this invention, include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water. Specific pharmaceutically-acceptable carriers are described in US-A-4,401,663, Buckwalter, et al, issued August 30, 1983; EP-A-0089710, LaHann, et al, published September 28, 1983; and EP-A-0068592, Buckwalter, et al, published January 5, 1983. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, aqueous ethanol, sesame oil, corn oil, and combinations thereof.

Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring, and flavoring agents. Preferred carriers for oral administration include ethyl oleate, methyl cellulose, gelatin, propylene glycol, cottonseed oil, sesame oil, peanut oil, corn oil, soybean oil, oil and water emulsions, and self-emulsifying oils either as free-flowing liquids or encapsulated in soft gelatin capsules. Specific examples of pharmaceutically-acceptable carriers and excipients that may be used to formulate oral dosage forms, which may be used in formulating oral dosage forms containing monoalkenamides, are described in US-A-3,903,297. Robert, issued September 2, 1975. Techniques and compositions for making solid oral dosage forms are described in Marshall, "Solid Oral Dosage Forms", *Modern Pharmaceutics*, Vol. 7, (Banker and Rhodes, editors), 359-427 (1979).

Specific systemic and topical formulations useful in this invention are described in the following Patents or Patent Applications, relating to specific capsaicin analogs and methods of treatment; US-A-4,401,663, Buckwalter, et al, issued August 30, 1983; EP-A-0089710; La Hann, et al, published September 28, 1983; EP-A-0068590, Buckwalter, et al, published January 5, 1983; and EP-A-0068592, Buckwalter, et al, published January 5, 1983. Topical vehicles, useful herein, are disclosed in the following: "Improved Penetrating Topical Pharmaceutical Compositions Combining 1-dodecylazacycloheptan-2-one", US-A-4,557,934; "Penetrating Topical Pharmaceutical Compositions Containing N-(1-hydroxy-ethyl)-pyrrolidone", US-A-4,537,776; and "Compounds Useful for Producing Analgesia", US-A-4,493,848.

Dosages required, as well as methods of administration, are dependent on the type of non-steroidal employed, the physical condition of the patient, the severity of the pain which must be prevented or alleviated, the relative severity and importance of adverse side effects, and other factors within the judgment of the physician. The preferred method of administration in most cases will be orally.

The maximum dosage of the preferred capsaicin analogue vanillyloleamide (VO) which would normally be administered orally to an average adult without unacceptable side effects is about 2000 mg (35.4 mg/kg). The minimum effective dosage is about 50 mg (0.85 mg/kg). The maximum dosage of a non-steroidal which can be administered to the average adult is also about 2000 mg (35.4 mg/kg). Thus, the maximum allowable dosage of the combination will be about 2000 mg (35.4 mg/kg). It should be noted that a sub-effective dosage of one compound may effectively potentiate the other compound; therefore, less-than-minimum dosages of each component may be utilized in some cases. Thus, when dealing with safe and effective dosage levels of the present invention, it is more appropriate to speak of safe and effective dosages of the combination rather than of the individual components.

The compositions and combinations of this invention can be used to treat and prevent pain and inflammation associated with certain diseases, particularly muscular-skeletal disorders, and to provide analgesia in various disorders at the deeper structures, muscles, tendons, bursa and joints associated with disease and trauma, and in various other conditions in which capsaicinoids and/or non-steroidals have heretofore been used to alleviate pain and discomfort.

The compositions of the instant invention are normally administered either topically or orally.

The following non-limiting Examples illustrate the compositions of the present invention.

EP 0 149 545 B1

Example I

An analgesic composition for oral administration was made using the following ingredients:

5	N-vanillyl-9E-octadecenamide	120 mg
	Ibuprofen	30 mg
	Methylcellulose	30 mg
10	Saline	6.0 ml

The methylcellulose suspending agent was dissolved in the saline to yield a 0.5% solution, to which the two drugs were added. A homogeneous suspension was achieved by the aid of sonication. Male mice weighing approximately 25 g were dosed by gavage with 250 mg/kg of the mixture. Analgesic activity was demonstrated using the phenylquinone writhing test mixture. Analgesic activity was demonstrated using the phenylquinone writhing test.

Example II

An analgesic composition for oral administration was made using the following ingredients:

20	N-vanillyl-9E-octadecenamide	120 mg
	Ibuprofen	30 mg
25	Ethyl oleate	6.0 ml

The two analgesic agents were suspended in the ethyl oleate with the aid of sonication, and analgesic activity was demonstrated using the phenylquinone writhing test.

Example III

A composition for oral administration is made with the following components:

		Bulk	Individual Tablet
35	N-vanillyl-9,12-octadecadienamide	140 g	350 mg
	Ibuprofen	35 g	90 mg
	Starch	12 g	30 mg
40	Magnesium stearate	2 g	5 mg
	Microcrystalline cellulose	40 g	100 mg
45	Colloidal silicon dioxide	1 g	2.5 mg
	Povidone	5 g	12.5 mg

The above ingredients are admixed in bulk and formed into compressed tablets, using tableting methods known in the art, each containing 590 mg of the mixture. One such tablet is administered orally to a 60 kg human, producing analgesia.

Example IV

A composition for transdermal topical delivery is made by admixing the following components:

55	N-vanillyl-9,12,15[E,E,E]-octadecatrienamide	4.0%
	Ibuprofen	1.0%
60	Myristyl alcohol	1.0%
	Propylene glycol	94.0%

Approximately 4.0 ml of the lotion is applied to an 80 sq cm portion of the skin of a 60 kg human, producing analgesia.

EP 0 149 545 B1

Effectiveness in Providing Analgesia Phenylquinone Writhing Tests

The extent of analgesia obtained was determined using the phenylquinone writhing test model. Groups of eight male mice weighing between approximately 25 and 30 g were dosed orally by gavage with the analgesic composition to be tested. Identical groups of mice were dosed with control compositions. Three hours after this initial administration, the mice were injected intraperitoneally with a 0.2% solution of phenylbenzoquinone in aqueous ethanol. The ability of the analgesic compositions tested to relieve the discomfort induced was measured by counting the number of abdominal contractions, or "writhes", occurring in each mouse during a 10 minute period beginning 10 minutes after injection of the phenylbenzoquinone solution. The results are expressed as a percent of the "writhing" response observed in the vehicle control group.

Example V

An analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9-octadecenamide	120 mg
Ibuprofen	30 mg
Methylcellulose	30 mg
Saline	6.0 ml

The methylcellulose suspending agent was dissolved in the saline to yield a 0.5% solution, to which the two drugs were added. A homogeneous suspension was achieved by the aid of sonication. The analgesic efficacy of this formulation was evaluated by dosing the mice by gavage with a sufficient dosage to provide 250 mg/kg of the mixture. The analgesic strength of the treatment was assessed using the "writhing" method described above. The efficacy of the combination was compared with that of similar formulations lacking the octadecenamide, the ibuprofen, or both.

Treatment	% Writhing Response
Methylcellulose alone	100
Ibuprofen (50 mg/kg)	114
Octadecenamide (200 mg/kg)	48
Octadecenamide (200 mg/kg) + ibuprofen (50 mg/kg)	2

In this case, the addition of an ineffective dose of ibuprofen to a moderately effective dose of octadecenamide resulted in a greatly potentiated analgesic effect.

Example VI

An analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9-octadecenamide	120 mg
Ibuprofen	30 mg
Ethyl oleate	6.0 ml

The two analgesics were suspended in ethyl oleate with the aid of sonication, and evaluated for analgesic efficacy exactly as described in Example X.

Treatment	% Writhing Response
Ethyl oleate alone	100
Octadecenamide (200 mg/kg)	36
Ibuprofen (50 mg/kg)	154
Octadecenamide (200 mg/kg) + ibuprofen (50 mg/kg)	5

EP 0 149 545 B1

Although the response of the group receiving 50 mg/kg of ibuprofen alone did not vary significantly from that of the control group, the addition of this sub-effective amount of ibuprofen to the octadecenamide greatly potentiated its analgesic effect. Further, the combination of ibuprofen with the octadecenamide can provide anti-inflammatory/anti-arthritis efficacy lacking in N-vanillyl-9-octadecenamide and related capsaicin analogs.

Example VII

In order to determine the preferred dosages of the capsaicinoid/non-steroidal combination in the rat, a 2:1 octadecenamide:ibuprofen analgesic composition for oral administration was made using the following ingredients:

N-vanillyl-9E-octadecenamide	100 mg
Ibuprofen	50 mg
Ethyl oleate/benzyl alcohol (98:2 vol/vol)	5 ml

The two analgesics were suspended in the ethyl oleate solution with the aid of sonication, and varying dosages of the combination, as well as the individual components, were evaluated for analgesic efficacy as described in Example X.


Treatment	% Writhing Response
Ethyl oleate solution alone	100
50 mg/kg ibuprofen	150
100 mg/kg octadecenamide	83
400 mg/kg octadecenamide	21
75 mg/kg 2:1 octadecenamide: ibuprofen combination	40
150 mg/kg 2:1 octadecenamide:	6
300 mg/kg 2:1 octadecenamide: ibuprofen combination	0.5

All three dosage levels of the combination produced a significant analgesic effect, although the 75 mg/kg dosage produced less analgesia than the other two dosages. Preferred dosage levels will depend on the severity of the pain to be treated, the relative severity of adverse side effects, and other factors within the judgment of the physician.

Although neither 50 mg/kg ibuprofen nor 100 mg/kg octadecenamide provided significant analgesia by themselves, the 150 mg/kg combination (100 mg/kg octadecenamide + 50 mg/kg ibuprofen) demonstrated an extremely strong analgesic effect. Furthermore, only 150 mg/kg of the 2:1 combination produced a greater analgesic effect than 400 mg/kg of octadecenamide alone, and only 75 mg/kg of the 2:1 combination (sub-effective amounts of both components) produced a greater analgesic effect than 100 mg/kg of octadecenamide alone. These results indicate a synergistic increase in analgesia when the two analgesics are combined.

Claims


1. An analgesic composition characterised in that it comprises a safe and effective amount of:
 - a) an analgesic compound of the general formula



wherein R₁ is selected from OH and OCH₃, R₂ is selected from OH and



5 R_3 is selected from C_1-C_4 alkyl and phenyl, X is selected from



10


and R is selected from $C_{11}-C_{23}$ *cis* alkenyl, $C_{11}-C_{23}$ alkynyl, $C_{11}-C_{23}$ alkadienyl and $C_{11}-C_{23}$ methylene substituted alkane;

15 b) an arylalkanoic non-steroidal analgesic selected from ibuprofen, naproxen, ketoprofen, fenoprofen, suprofen, flurbiprofen, benoxaprofen, piroprofen and carprofen; and

c) a pharmaceutically-acceptable carrier; wherein the weight ratio of (a):(b) is from 20:1 to 1:20.

2. A composition according to Claim 1, characterized in that R_1 and R_2 are both OH and X is

20



3. A composition according to Claim 1, characterized in that R_1 is OCH_3 , R_2 is OH, and X is

25



30 4. A composition according to Claim 3, characterized in that R is a $C_{16}-C_{21}$ *cis* alkenyl or $C_{16}-C_{21}$ alkadienyl.

5. A composition according to Claim 1, characterized in that R_1 is OCH_3 , R_2 is OH, X is

35



and R is $C_{16}-C_{21}$ alkadienyl.

40

6. A composition according to Claim 1, characterized in that the capsaicinoid is N-vanillyl-9-octadecenamide.


Patentansprüche

45

1. Eine analgesische Zusammensetzung, dadurch gekennzeichnet, dass sie eine sichere und wirksame Menge

a) einer analgesischen Verbindung der allgemeinen Formel

50



55

worin R_1 ausgewählt ist aus OH und OCH_3 , R_2 ausgewählt ist aus OH und


60



R_3 ausgewählt ist aus C_1-C_4 -Alkyl und Phenyl, X ausgewählt ist aus

65


EP 0 149 545 B1




und R ausgewählt ist aus einem C₁₁—C₂₃-cis-Alkenyl-, C₁₁—C₂₃-Alkynyl-, C₁₁—C₂₃-Alkadienyl und einem C₁₁—C₂₃-Methylen-substituierten Alkanrest,

b) einer nicht-steroiden, analgesischen Arylalkansäureverbindung, ausgewählt aus Ibuprofen, Naproxen, Ketoprofen, Fenoprofen, Suprofen, Flurbiprofen, Benoxaprofen, Pirprofen und Carprofen, und c) einen pharmazeutisch zulässigen Träger enthält, worin das Gewichtsverhältnis von (a) zu (b) 20:1 bis 1:20 beträgt.

2. Eine Zusammensetzung gemäss Anspruch 1, dadurch gekennzeichnet, dass R₁ und R₂ beide OH und X



3. Eine Zusammensetzung gemäss Anspruch 1, dadurch gekennzeichnet, dass R₁ OCH₃, R₂ OH und X



4. Eine Zusammensetzung gemäss Anspruch 3, dadurch gekennzeichnet, dass R einen C₁₆—C₂₁-cis-Alkenyl oder einen C₁₆—C₂₁-Alkadienylrest bedeutet.

5. Eine Zusammensetzung gemäss Anspruch 1, dadurch gekennzeichnet, dass R₁ OCH₃, R₂ OH, X




und R ein C₁₆—C₂₁-Alkadienylrest ist.


6. Eine Zusammensetzung gemäss Anspruch 1, dadurch gekennzeichnet, dass das Capsaicinoid N-Vanillyl-9-octadecenamid ist.

Revendications

1. Composition analgésique, caractérisée en ce qu'elle comprend une quantité sans danger et efficace: a) d'un composé analgésique de formule générale



dans laquelle R₁ est choisi parmi OH et OCH₃, R₂ est choisi parmi OH ou OCR₃, R₃ est choisi parmi un groupe alkyle en C₁—C₄ et un groupe phényle, X est choisi parmi



et R est choisi parmi un groupe cis-alcényle en C₁₁—C₂₃, alcynyle en C₁₁—C₂₃, alcadiényle en C₁₁—C₂₃ et un alcane substitué par un méthylène en C₁₁—C₂₃;

b) d'un analgésique arylalcanoïque non stéroïdien choisi parmi l'ibuprofen, le naproxen, le kétoprofen, le fénoprofen, le suprofen, le flurbiprofen, le benoxoprofen, le pirprofen et le carprofen; et

c) d'un véhicule pharmaceutiquement acceptable; le rapport pondéral de (a) à (b) étant de 20:1 à 1:20.

EP 0 149 545 B1

2. Composition selon la revendication 1, caractérisée en ce que R₁ et R₂ sont tous deux OH et X est

5



3. Composition selon la revendication 1, caractérisée en ce que R₁ est OCH₃, R₂ est OH et X est

10



4. Composition selon la revendication 3, caractérisée en ce que R est un groupe cis-alcényle en C₁₈—C₂₁ ou alcadiényle en C₁₆—C₂₁.

15

5. Composition selon la revendication 1, caractérisée en ce que R₁ est OCH₃, R₂ est OH, X est

20



et R est un groupe alcadiényle en C₁₆—C₂₁.

6. Composition selon la revendication 1, caractérisée en ce que le capsaïcinoïde est le N-vanillyl-9-octadécénamide.

25

30

35

40

45

50

55

60

65